Physician profile
Dina Ibrahim
NPI 1780625376
$10,849.87
in general payments reported to CMS, 2019-2025
66 companies · $3,899 in 2025
The $3,899 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,571 · 2020: $226 · 2021: $340 · 2022: $551 · 2023: $806 · 2024: $3,456 · 2025: $3,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,954 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,954.13 |
| Education | $207.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,106.95 | 2019-2025 | |
| Pfizer INC. | $932.07 | 2019-2025 | |
| Lilly USA, LLC | $646.50 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $571.90 | 2019-2024 | Opdualag, Opdivo |
| Exelixis INC. | $456.27 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $441.85 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Astrazeneca Pharmaceuticals LP | $438.23 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $426.31 | 2019-2025 | Erleada, Rybrevant, Talvey |
| Glaxosmithkline, LLC. | $396.25 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $367.28 | 2019-2025 | |
| Astellas Pharma US INC | $315.42 | 2023-2025 | Vyloy, Xospata, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $314.34 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Merck Sharp & Dohme LLC | $294.35 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $278.85 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.05 | 2023-2025 | Gilotrif |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $260.92 | 2023-2025 | Tecentriq, Polivy, Phesgo |
| Abbvie INC. | $246.13 | 2019-2025 | |
| Celgene Corporation | $202.05 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Sobi, INC | $168.27 | 2023-2025 | |
| Medtronic Vascular, INC. | $158.57 | 2019 | |
| Seagen INC. | $152.01 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $139.27 | 2022-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $138.00 | 2019-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $131.35 | 2025 | Ultomiris |
| Tersera Therapeutics LLC | $123.77 | 2019-2025 | Quzyttir |
| Stemline Therapeutics INC. | $108.36 | 2024-2025 | Orserdu |
| Springworks Therapeutics, INC. | $103.92 | 2024-2025 | Ogsiveo |
| Puma Biotechnology, INC. | $103.88 | 2024-2025 | |
| Pharmaessentia USA Corporation | $91.26 | 2023-2025 | Besremi |
| Array Biopharma INC | $89.71 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $84.63 | 2020-2025 | Onivyde |
| Agios Pharmaceuticals, INC. | $82.13 | 2025 | Pyrukynd |
| Caris Mpi, INC. | $80.85 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $75.69 | 2019-2025 | Trodelvy |
| Amgen INC. | $68.87 | 2019-2023 | Lumakras |
| Beigene USA, INC. | $65.65 | 2024 | Brukinsa |
| Tactile Systems Technology INC | $65.57 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Octapharma USA, INC. | $62.81 | 2019 | |
| Incyte Corporation | $60.21 | 2019-2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $49.05 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $47.63 | 2020-2023 | Xpovio |
| Tempus Ai, INC | $41.52 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $38.32 | 2024 | Krazati |
| Myriad Genetic Laboratories, INC. | $37.01 | 2024 | Myrisk |
| Kite Pharma, INC. | $35.72 | 2020-2023 | |
| Medtronic, INC. | $35.24 | 2024 | Osteocool Rf Ablation System |
| Amneal Pharmaceuticals LLC | $34.32 | 2024-2025 | Alymsys, Neupogen, Neulasta |
| Pharmacosmos Therapeutics INC. | $32.39 | 2024 | Monoferric |
| Syndax Pharmaceuticals, INC. | $31.02 | 2025 | |
| Iovance Biotherapeutics, INC. | $27.06 | 2025 | Amtagvi |
| Deciphera Pharmaceuticals INC. | $26.05 | 2024 | Tgct, Qinlock |
| Rigel Pharmaceuticals, INC. | $25.89 | 2024 | Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $23.28 | 2024 | |
| Geron Corporation | $23.22 | 2025 | Rytelo |
| Shield Therapeutics INC | $22.73 | 2025 | |
| Biomarin Pharmaceutical INC. | $22.59 | 2024 | Roctavian |
| Sun Pharmaceutical Industries INC. | $22.01 | 2019 | |
| Dova Pharmaceuticals | $20.76 | 2019 | |
| Recordati_rare_diseases_inc. | $19.18 | 2025 | Sylvant |
| Adc Therapeutics America, INC. | $18.40 | 2025 | |
| Portola Pharmaceuticals, LLC | $18.18 | 2020 | |
| Immunogen, INC. | $16.76 | 2023 | Elahere |
| Accord Healthcare, INC. | $16.13 | 2025 | |
| Tesaro, INC. | $15.59 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.42 | 2025 | Danziten |
| Pharmacyclics LLC, An Abbvie Company | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.